A Randomized, double-blind, placebo-controlled pilot study of KB001 in mechanically-ventilated patients colonized with pseudomonas aeruginosa

KaloBios Pharmaceuticals, Inc.0 个研究点开始时间: 2008年1月31日最近更新: 2012年3月19日

试验速览

暂无简介。

•1. Provision of written informed consent obtained from patient or patient’s surrogate if unconscious or altered sensorium
•2. Age =18 years
•3. On mechanical ventilation and expected to remain mechanically ventilated for at least 3 days
•4. Documented pulmonary Pa colonization (> 10 colonies per plate by semi-quantitive culture or = 1000 CFU/mL by quantitative culture or PCR from ETA or = 100 CFU/mL by BAL)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Patients with known chronic pulmonary infection with Pa (i.e., patients with cystic fibrosis)
•2. Patient currently diagnosed with PA VAP
•3. Change in systemic antibiotic therapy active against gram negative bacteria within 72 hours prior to screening culture used for documenting pulmonary Pa colonization for study entry
•4. Patients not expected to survive at least 3 days
•5. Patient expected to be transferred to another institution during the 28 day study period
•6. Women of childbearing potential with a positive serum pregnancy test
•7. Use of an investigational medication within 4 weeks prior to randomization
•8. Any other reason, which in the opinion of the Investigator would prevent the patient from completing participation in the study

发起方

KaloBios Pharmaceuticals, Inc.